Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295757 | 1.00 | EPHX1 (0.48) | EPHX1SLC7A5CA2CA9ALPI | |
| SCHEMBL901961 | 1.00 | EPHX1 (0.48) | EPHX1SLC7A5CA2CA9ALPI | |
| SCHEMBL1912535 | 0.91 | CTSS (0.49) | CA2CA9KLK5CTSSCTSK | |
| Hydrochloric Acid SCHEMBL1912533 | 0.90 | SRR (0.49) | CA2CA9KLK5CTSSCTSK | |
| SCHEMBL6177689 | 0.84 | ATM (0.48) | SLC7A5CA2CA9ATMKLK5 | |
| SCHEMBL12889353 | 0.84 | SLC15A1 (0.52) | SLC7A5KLK5 | |
| SCHEMBL9196126 | 0.83 | ATM (0.47) | SLC7A5CA2CA9ATMKLK5 | |
| SCHEMBL6343323 | 0.82 | EPHX1 (0.53) | EPHX1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL27846893 | 0.82 | EPHX1 (0.53) | EPHX1SLC7A5ALPIPKMPTGS1 | |
| SCHEMBL2632623 | 0.82 | EPHX1 (0.53) | EPHX1SLC7A5ALPIPKMPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834220-B1 | 4-HYDROXY-ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9409892-B2 | 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors | FIBROGEN, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2834220-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | Fibrogen, Inc. (US) | 2015-02-11 | — | — | EP | disclosed |
| US-20150038528-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. | 2015-02-05 | — | — | US | disclosed |
| WO-2013134660-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | FIBROGEN, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| CN-102321020-A | The lxr receptor regulator | FOURNIER LAB SA | 2012-01-18 | — | — | CN | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| CN-101248043-A | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors useful for the treatment of hyperlipidaemic conditions | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | CN | disclosed |
| CN-1950340-A | LXR receptor modulators | FOURNIER LAB SA (FR) | 2007-04-18 | — | — | CN | disclosed |
| CN-1268610-C | Sulfonamide derivatives | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| CN-1509269-A | Sulfonamide derivatives | ��˹��ŵ�� | 2004-06-30 | — | — | CN | disclosed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038528-A1 | 4 -HYDROXY- ISOQUINOLINE COMPOUNDS AS HIF HYDROXYLASE INHIBITORS | EGLN3, HIF1AN, EGLN2 | EPHX1 890/4885SLC7A5 3479/4885CA2 977/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | EPHX1 1552/4885SLC7A5 4114/4885CA2 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.